BIOPOR Bioporto A/S

Rights issue fully subscribed

Rights issue fully subscribed

April 6, 2020

Announcement no. 8

Rights issue fully subscribed

By company announcement no. 6 of March 16, 2020, BioPorto A/S (“BioPorto”) announced the initiation of a right issue (the “Offering”) with pre-emptive subscription rights for the Company’s existing shareholders allowing for subscription of up to 24,992,054 new shares with a nominal value of DKK 1 each (the “New Shares”).

The subscription period for the New Shares has expired, and BioPorto is pleased to announce that all of the New Shares have been subscribed for. The offering is thus fully subscribed for.

The allocation of subscription orders for remaining shares will be communicated to the individual investors in due course.

The Offering will be completed when payment of subscription amounts have taken place and the New Shares have been registered with the Danish Business Authority, expectedly on April 14, 2020. The expected timetable in BioPorto’s company announcement no. 6 of March 16, 2020 remains unchanged.

Yours sincerely

BioPorto A/S

For further information, please contact:

Peter Mørch Eriksen, CEO

Ole Larsen, CFO

Telephone , e-mail:

About BioPorto

BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR].

Attachment

EN
06/04/2020

Underlying

BIOPORBioporto A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bioporto A/S

 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

BioPorto attends the Association for Diagnostics & Laboratory Medicine...

BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants. July 28, 2025News Release BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants. Laboratory medicine continues to focus on kidney diagnostics. BioPorto is pleased to announce its attendance and the general multiple NGAL and Acute Kidney Injury (AKI) focused elements of the Association for Diagnostics Medicine meeting, this year held in...

July 28, 2025 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

Påbegyndelse af kommercialisering af ProNephro AKI (NGAL) til diagnost...

Påbegyndelse af kommercialisering af ProNephro AKI (NGAL) til diagnostisk brug i USA 27. juni, 2025Meddelelse nr. 18 Påbegyndelse af kommercialisering af ProNephro AKITM (NGAL) til diagnostisk brug i USA KØBENHAVN, DANMARK og BOSTON, MA, USA, 27. juni 2025 – BioPorto A/S ("BioPorto" eller "Selskabet") (CPH:BIOPOR) meddelte i dag, at de har påbegyndt kommercialisering i USA af ProNephro AKITM (NGAL) til klinisk anvendelse i risikostratificering af moderat til svær AKI for patienter i alderen 3 måneder til 21 år, ved at modtage den første købsordre på ProNephro AKITM (NGAL) til det amerik...

June 27, 2025 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

Initiation of commercialization of ProNephro AKI (NGAL) for diagnostic...

Initiation of commercialization of ProNephro AKI (NGAL) for diagnostic use in the US June 27, 2025Announcement no. 18 Initiation of commercialization of ProNephro AKITM (NGAL) for diagnostic use in the US COPENHAGEN, DENMARK and BOSTON, MA, USA, June 27, 2025 – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) today announced the initiation of commercialization in the US of ProNephro AKITM (NGAL) for clinical use in risk stratification for moderate-to-severe AKI for patients aged 3 months to 21 years, by receiving the first purchase order of ProNephro AKITM (NGAL) for the US market...

June 27, 2025 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

Tildeling af Warrants

Tildeling af Warrants 12. juni 2025Meddelelse nr. 17                                                                          Tildeling af Warrants København, Danmark, den 12. juni 2025 (GLOBE NEWSWIRE) – Bestyrelsen for BioPorto A/S ("BioPorto" eller "Selskabet") (CPH:BIOPOR) har i dag besluttet at udstede i alt 3.250.000 warrants til Selskabets Extended Leadership Team. Hver warrant giver indehaveren ret til at tegne én aktie i BioPorto til en udnyttelseskurs på 1,39 kr. pr. aktie, svarende til lukkekursen på Nasdaq Copenhagen i dag. Warrants udstedes i henhold til § 18 a i Selskabets...

June 12, 2025 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

Grant of Warrants

Grant of Warrants 12 June 2025 Announcement no. 17                                                                          Grant of Warrants Copenhagen, Denmark, June 12, 2025, (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has today decided to issue a total of 3,250,000 warrants to the Extended Leadership Team. Each warrant entitles the holder the right to subscribe for one share in BioPorto at an exercise price of DKK 1.39 per share, corresponding to the closing price today on Nasdaq Copenhagen. The warrants are issued in accord...

June 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch